296 results on '"Sher, Lawrence"'
Search Results
2. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis
3. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
4. The Supreme Court's Recent Rulings-A Boon For Government Contractors?
5. Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study
6. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma
7. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
8. The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma
9. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials
10. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
11. Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
12. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial
13. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study
14. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study
15. Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2)
16. Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study
17. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis
18. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
19. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis
20. 385. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to 5- to 11-Year-Old Children Who Previously Received 3 Doses of Original BNT162b2
21. 362. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to Toddlers and Children 6 Months to < 5 Years of Age Who Previously Received Original BNT162b2 as a 3-Dose Primary Series
22. Phase 2b Randomized Trial of OX40 Inhibitor Telazorlimab for Moderate-to-Severe Atopic Dermatitis
23. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
24. DUPILUMAB REDUCES RESCUE SYSTEMIC CORTICOSTEROID USE IN CHILDREN WITH UNCONTROLLED MODERATE TO SEVERE ASTHMA REGARDLESS OF PRIOR EXACERBATION HISTORY
25. Efficacy of dupilumab in patients with uncontrolled, moderate‐to‐severe asthma with fungal sensitization
26. Dupilumab reduces systemic corticosteroid exposure in children with uncontrolled moderate-to-severe asthma regardless of prior exacerbations
27. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
28. Equity: Ownership by Minorities and Women of Research Projects.
29. New Federal Ban Prohibits TikTok On Devices Used On Government Contracts
30. Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial
31. Student Created Calculus Movies Using Computers and the TI-92.
32. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial
33. Dupilumab long-term efficacy in patients with non–OCS–dependent asthma with and without evidence of allergic asthma.
34. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
35. Dupilumab Efficacy in Children With Atopic Dermatitis Aged 6 Months to 5 Years With and Without Atopic Comorbidities
36. Dupilumab improves type 2 comorbidity outcomes in patients with eosinophilic esophagitis and comorbid disease at baseline: from Parts A and B of LIBERTY-EoE-TREET
37. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
38. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials
39. The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma
40. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
41. A Classroom Note on Generating Examples for the Laws of Sines and Cosines from Pythagorean Triangles
42. Baseline Clinical and Immunologic Characteristics of Children Screened in the Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON) Trial
43. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
44. Flight Simulator: Use of SpaceGraph Display in an Instructor/Operator Station. Final Report.
45. Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study
46. LONG-TERM EFFICACY OF DUPILUMAB IN ORAL CORTICOSTEROID-DEPENDENT PATIENTS WITH ASTHMA: LIBERTY ASTHMA TRAVERSE
47. Effect of dupilumab on improving physical activity in patients with severe asthma
48. Dupilumab sustains long-term OCS reduction in OCS-dependent asthma patients
49. Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma
50. 27406 Dupilumab improves signs and symptoms of severe atopic dermatitis in children aged 6–11 years with and without comorbid asthma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.